Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
November 15, 2011

Boston PolarCath dilatation system found to reduce restenosis rate

Boston Scientific's PolarCath peripheral dilatation system has demonstrated positive results from the COBRA clinical trial, which investigated post-dilation of nitinol stents using CryoPlasty therapy.

Boston Scientific’s PolarCath peripheral dilatation system has demonstrated positive results from the COBRA clinical trial, which investigated post-dilation of nitinol stents using CryoPlasty therapy.

CryoPlasty therapy uses nitrous oxide to fill an angioplasty balloon within a blocked artery to treat atherosclerotic lesions in the peripheral arteries.

The COBRA trial randomised 76 patients with 90 superficial femoral artery lesions to CryoPlasty therapy or conventional balloon angioplasty for post-dilation of nitinol stents.

The prospective, randomised, multicentre trial showed a 47% relative reduction in binary restenosis rates for patients treated with PolarCath system compared to stenting with conventional balloon angioplasty.

In the study, the primary endpoint was the rate of binary in-segment restenosis determined by duplex ultrasonography, while the secondary endpoint included change in the ankle-brachial index from baseline in 12 months.

Principal investigator of the study Subhash Banerjee said CryoPlasty therapy can reduce binary restenosis at 12 months.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
The powerful networks advancing life sciences in Charleston | USA
The power of infrastructure: How Charleston | SC | USA is expanding horizons for life science companies

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU